Published in Oncogene on April 18, 1996
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev (2001) 11.25
Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A (1997) 3.37
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci U S A (2003) 2.18
WAVE2 deficiency reveals distinct roles in embryogenesis and Rac-mediated actin-based motility. EMBO J (2003) 1.98
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol (2003) 1.27
Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol (1999) 1.23
Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proc Natl Acad Sci U S A (1999) 1.12
Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol (2003) 1.04
Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells. Oncogene (2006) 0.97
Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway. Mol Cell Biol (2004) 0.90
Co-regulation of p16INK4A and migratory genes in culture conditions that lead to premature senescence in human keratinocytes. J Invest Dermatol (2005) 0.89
Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer (2005) 0.88
Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras. Virology (2006) 0.87
Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells. Cancer Cell Int (2006) 0.80
Immortalized cells as experimental models to study cancer. Cytotechnology (2004) 0.79
Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest (2016) 0.76
Immortalization of Primary Keratinocytes and Its Application to Skin Research. Biomol Ther (Seoul) (2015) 0.75
Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses? Cell Mol Life Sci (2017) 0.75
A computational modelling framework to quantify the effects of passaging cell lines. PLoS One (2017) 0.75
Epigenetic Reprogramming of Lineage-Committed Human Mammary Epithelial Cells Requires DNMT3A and Loss of DOT1L. Stem Cell Reports (2017) 0.75
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med (1996) 4.51
Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst (1998) 4.42
Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol (1996) 4.25
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Epidemiology of genital human papillomavirus infection. Epidemiol Rev (1988) 3.32
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev (1997) 2.65
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol (1992) 2.61
The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature (1983) 2.26
Detection of herpes simplex RNA in human sensory ganglia. Virology (1979) 2.23
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol (2001) 2.18
Limited transcription of the herpes simplex virus genome when latent in human sensory ganglia. J Virol (1982) 2.12
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 2.06
Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A (1994) 2.02
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol (1994) 1.97
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res (1996) 1.93
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol (1982) 1.88
Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol (1998) 1.84
Genital human papillomavirus infection in women who have sex with women. J Infect Dis (1998) 1.77
Evidence of prevalent genital-type human papillomavirus infections in adults and children. J Infect Dis (1990) 1.74
Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst (1997) 1.72
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70
Nucleotide sequence of the herpes simplex virus type 2 thymidine kinase gene. J Virol (1983) 1.70
Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol (2001) 1.66
Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart. J Virol (1985) 1.60
Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res (1995) 1.59
E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol (2001) 1.58
Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol (1996) 1.57
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Sequence and structural requirements of a herpes simplex viral DNA replication origin. Mol Cell Biol (1988) 1.55
Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2. J Virol (1981) 1.54
Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol (1988) 1.51
The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol (1989) 1.47
Cloning and characterization of oriL2, a large palindromic DNA replication origin of herpes simplex virus type 2. J Virol (1986) 1.44
Identification of proteins encoded by a fragment of herpes simplex virus type 2 DNA that has transforming activity. J Virol (1982) 1.42
Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3'-coterminal transcripts. J Virol (1986) 1.39
Identification of the E5 open reading frame of human papillomavirus type 16. J Virol (1988) 1.38
Structure of the transforming region of human cytomegalovirus AD169. J Virol (1984) 1.35
Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures. Proc Natl Acad Sci U S A (1984) 1.34
Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res (1995) 1.32
Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis (1989) 1.26
HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology (1993) 1.25
Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology (1994) 1.24
Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol (1998) 1.24
Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope. J Virol (1989) 1.20
The G(2) checkpoint is maintained by redundant pathways. Mol Cell Biol (1999) 1.18
Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol (1992) 1.18
The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev (1996) 1.17
Cervical carcinoma: detection of herpes simplex virus RNA in cells undergoing neoplastic change. Int J Cancer (1980) 1.16
Analysis of viral DNA sequences in hamster cells transformed by herpes simplex virus type 2. Proc Natl Acad Sci U S A (1980) 1.16
Cloning of Herpes simplex virus 2 DNA fragments in a plasmid vector. Gene (1980) 1.16
Organization of the left-hand end of the herpes simplex virus type 2 BglII N fragment. J Virol (1984) 1.15
Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev (2001) 1.14
Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis (1995) 1.14
Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology (1988) 1.12
Location and cloning of the herpes simplex virus type 2 thymidine kinase gene. J Virol (1980) 1.11
Comparison of Southern transfer hybridization and dot filter hybridization for detection of cervical human papillomavirus infection with types 6, 11, 16, 18, 31, 33, and 35. Am J Clin Pathol (1990) 1.08
Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochem J (1996) 1.07
Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ (1997) 1.02
Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18. J Virol (1991) 1.01
Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. In Vitro Cell Dev Biol Anim (1997) 1.00
Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology (1994) 0.98
HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women. Rheumatology (Oxford) (2004) 0.98
Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis (1997) 0.98
Serologic evidence of herpes simplex virus 1 infection and oropharyngeal cancer risk. Cancer Res (2001) 0.96
Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol (1991) 0.96
The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. Virology (1994) 0.96
Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11. J Virol (1992) 0.95
p21CIP1 is not required for the early G2 checkpoint response to ionizing radiation. Cancer Res (1995) 0.95
Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res (1998) 0.93
Transformation of rat cells by the hybrid virus Ad2(2+) HEY. J Gen Virol (1979) 0.93
Comparative virologic studies of condylomata acuminata reveal a lack of dual infections with human papillomaviruses. J Infect Dis (1991) 0.93
Papillomavirus capsids: a new approach to identify serological markers of HPV infection. J Natl Cancer Inst (1994) 0.92
Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes. Proc Natl Acad Sci U S A (1993) 0.91
Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology (1991) 0.91
The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev (2000) 0.90
Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis (2000) 0.90
HSV, CMV, and HPV in human neoplasia. J Invest Dermatol (1984) 0.88
Sequence variation in the noncoding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis. J Infect Dis (1993) 0.88
Inhibiting CDK inhibitors: new lessons from DNA tumor viruses. Trends Biochem Sci (1998) 0.88
Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology (1995) 0.87
Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis. Tissue Antigens (2005) 0.86
Detection of nucleic acid sequences in cervical tumors. Gynecol Oncol (1981) 0.86
Identification of CIP-1-associated regulator of cyclin B (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle. J Biol Chem (2000) 0.86
Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies. Virology (1998) 0.85
Sequence and antigenic diversity in two immunodominant regions of the L2 protein of human papillomavirus types 6 and 16. J Infect Dis (1993) 0.85
Humoral immune response to human papillomavirus infection. Clin Dermatol (1997) 0.84
Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Radiat Oncol Biol Phys (1996) 0.84
Serological and molecular evidence of rhesus papillomavirus type 1 infections in tissues from geographically distinct institutions. J Gen Virol (1995) 0.83
The association of human papillomavirus antibodies with cervical cancer risk. Cancer Epidemiol Biomarkers Prev (1993) 0.81
Herpesvirus-specific RNA and protein in carcinoma of the uterine cervix. Proc Natl Acad Sci U S A (1982) 0.80
Plasmid mediated mutagenesis of a cellular gene in transfected eukaryotic cells. Nucleic Acids Res (1987) 0.78